We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study.
- Authors
ETMINAN, M.; LÉVESQUE, L.; FITZGERALD, J. M.; BROPHY, J. M.
- Abstract
Background Gastrointestinal injuries including gastric ulcers have been reported with oral bisphosphonate therapy. However, the risk of the more serious upper gastrointestinal bleeding (UGB) especially in the community setting with these drugs remains unknown. Similarly, the risk of UGB among users of both bisphosphonates and non steroidal anti-inflammatory drugs (NSAIDs) in the community is also unknown. Aim To explore the risk of more serious UGB among users of bisphosphonates and the risk of UGB among users of both bisphosphonates and NSAIDs in the community. Methods We conducted a case-control study within a cohort of Quebec residents who had received a revascularization procedure from 1995 to 2004. Cohort members were followed up from the date of their first procedure until the earliest of: (1) study outcome, (2) date of death or (3) end of health care coverage. Cases were defined as those with the first diagnosis of a UGB. For each case, 20 controls were selected and matched to the cases by index date, age and cohort entry. Adjusted odds ratios for current use of bisphosphonates, NSAIDs and co-therapy of both drugs were computed. Results Within the initial cohort, 3253 incident cases of UGBs and corresponding 65 060 matched controls were identified. The adjusted odds ratio (OR) for UGB by current users of bisphosphonates was 1.01 (95% CI, 0.72–1.43). Current NSAID use was associated with an increased risk of UGB OR = 1.75; 95% CI, 1.53–1.99. The OR for use of bisphosphonates and NSAIDs was elevated OR = 2.00; 95% CI, 1.12–3.57. This risk was still elevated for users of bisphosphonates and COX-2 inhibitors [OR = 2.38 (95% CI, 1.26–4.50)]. Conclusion We found no evidence of an increase in the risk of UGB among current users of bisphosphonates. The risk of combined NSAID and bisphosphonate therapy was increased, but this risk was not higher than the risk for NSAID users alone.
- Subjects
DIPHOSPHONATES; GASTROINTESTINAL hemorrhage; NONSTEROIDAL anti-inflammatory agents; DIAGNOSIS; CLINICAL epidemiology
- Publication
Alimentary Pharmacology & Therapeutics, 2009, Vol 29, Issue 11, p1188
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2009.03989.x